Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

NCT01623323 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
705
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Optinose US Inc.